Strategic Investment for Future Growth Srinivas Sadu, Executive Chairman of Gland Pharma, commented on the expansion: "Our investments in global CDMO expansion, capacity enhancement in high-end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders." This capacity expansion aligns with Gland Pharma's strategy to diversify its product portfolio and tap into emerging pharmaceutical trends
Generally, IV Glutathione treatments are priced higher than oral supplements due to faster and more effective results
Gastrointestinal symptoms such as nausea, vomiting, and diarrhoeareported by a significant proportion of patients, particularly during dose escalationcan lead to dehydration and nutritional changes
You can also use the GuruFocus Stock Screener to find similar opportunities
Velilla S, Garcia-Medina JJ, Garcia-Layana A, Dolz-Marco R, Pons-Vazquez S, Pinazo-Duran M, et al